Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort
ImmunoTargets and Therapy · 2026-04 · Volume 15 · 1-11
DOI: 10.2147/itt.s603087 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift ImmunoTargets and Therapy, 2026-04. Verfasst von Małgorzata Mitura-Lesiuk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Oncology and Transplantology, University Children's Hospital, Lublin, Poland. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Hematology, Oncology and Transplantology, University Children's Hospital, Lublin, Poland.
- Student Scientific Society, Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland.
ORCID-Profile: Małgorzata Mitura-Lesiuk, Patrycja Najda, Oliwia Rdzanek, Julia Bogucka, Karolina Różycka, Maciej Dubaj, Joanna Zawitkowska
Zitieren
APA
Mitura-Lesiuk, M., Najda, P., Rdzanek, O., Bogucka, J., Różycka, K., Dubaj, M., & Zawitkowska, J. (2026). Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort. ImmunoTargets and Therapy, Volume 15, 1-11. https://doi.org/10.2147/itt.s603087
Vancouver
Mitura-Lesiuk M, Najda P, Rdzanek O, Bogucka J, Różycka K, Dubaj M, et al. Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort. ImmunoTargets and Therapy. 2026;Volume 15:1-11. doi:10.2147/itt.s603087
BibTeX
@article{MituraLesiuk2026,
author = {Mitura-Lesiuk, Małgorzata and Najda, Patrycja and Rdzanek, Oliwia and Bogucka, Julia and Różycka, Karolina and Dubaj, Maciej and Zawitkowska, Joanna},
title = {Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort},
journal = {ImmunoTargets and Therapy},
year = {2026},
volume = {Volume 15},
pages = {1--11},
doi = {10.2147/itt.s603087}
}
EUVIMED